Università di Pisa
Sistema bibliotecario di ateneo

Dipyridamole in Heart Failure due to Dilated Cardiomyopathy: A Pilot Study

Stea, Francesco and Havasi, Kálmán and Sicari, Rosa and Rózsavölgyi, Zoltán and Morales, Maria Aurora and Somfay, Attila and Picano, Eugenio and Varga, Albert (2016) Dipyridamole in Heart Failure due to Dilated Cardiomyopathy: A Pilot Study. Journal of Pharmaceutical Negative Results, 7 . pp. 46-52. ISSN 0976-9234

PDF - Published Version
Available under License Creative Commons Attribution Non-commercial Share Alike.

Download (1460Kb) | Preview


    Introduction: Dipyridamole (DIP) might be beneficial in heart failure (HF). It has been reported to improve symptoms in observational, small‑scale studies. The PRoFESS study for secondary prevention of stroke observed a reduction in the risk of HF with acetylsalicylic acid (ASA) plus DIP in comparison with clopidogrel. The present pilot study was aimed at assessing the clinical effects of DIP and ASA in dilated cardiomyopathy. Materials and Methods: Nineteen outpatients with nonischemic HF, New York Heart Association (NYHA) Class II, ejection fraction (EF) <40%, were randomized to ASA 25 mg, or ASA 25 mg plus DIP 200 mg (ASA + DIP), twice daily. They were evaluated at baseline and after 6 months for symptoms, EF, and exercise capacity through 6‑min walk test. Results: Eleven subjects were in the ASA group and 8 in the ASA + DIP. Dyspnea improved, without differences between the two arms: n = 6/5/0/0 for NYHA I/II/III/IV in ASA, n = 4/3/1/0 in ASA + DIP. EF increased in both groups (ASA: from 34 [28–35%] to 40 [32–46%]; ASA + DIP from 32.5 [25.75–34%] to 36 [31.5–46%]). No change in meters walked or points in the Borg scale was observed. In a similar population, an adequately powered study would need to recruit 38 subjects. Conclusion: The study, although underpowered, did not show any difference between the two treatment strategies. While this appears in contrast with previous studies, the strict inclusion criteria, the randomized, double‑blind design, and the clinical end‑points give strength to our findings. A properly sized trial would be within the capabilities of a single center.

    Item Type: Article
    Subjects: Area05 - Scienze biologiche > BIO/14 - Farmacologia
    Area06 - Scienze mediche > MED/11 - Malattie dell'apparato cardiovascolare
    Depositing User: Dr. Francesco Stea
    Date Deposited: 18 Apr 2016 09:31
    Last Modified: 18 Apr 2016 09:31
    URI: http://eprints.adm.unipi.it/id/eprint/2356

    Repository staff only actions

    View Item